BACE1 and Alzheimer disease: However, even though BACE1 inhibitors efficiently lower brain Aβ levels, clinical trials still have not demonstrated improvements in cognitive function when BACE1 inhibitors are administered to mild-to-moderate AD patients, calling into question the real worth of these potential anti-AD drugs and the designs of the clinical trials [26].